Is nosocomial Escherichia coli bacteremia a predictive risk factor for mortality?  by Tuon, Felipe F. et al.
b r a z j i n f e c t d i s . 2 0 1 4;1  8(1):92–94
The Brazilian Journal of
INFECTIOUS  DISEASES
www.elsev ier .com/ locate /b j id
Brief communication
Is nosocomial  Escherichia  coli bacteremia  a predictive  risk
factor for mortality?
Felipe F. Tuon ∗, Jaime L. Rocha, Fernanda A. Guadagnin, Márcia S. Alves
Division of Infectious and Parasitic Diseases, Hospital Universitário Evangélico de Curitiba, Curitiba, PR, Brazil
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 24 March 2013
Accepted  12 May 2013
Available  online 20 September 2013
Keywords:
a  b  s  t  r  a  c  t
The objective of this study was to determine risk factors associated with mortality in patients
with nosocomial Escherichia coli bacteremia from January 2009 to January 2011. In a retro-
spective  study the medical records of 88 patients over 18 years with nosocomial bacteremia
caused  by E. coli were analyzed. In univariate analysis several risk factors, including chronic
renal  failure, altered mental status, leukocytosis, and higher Charlson index of comorbidities
were  associated with mortality. In multivariate analysis only altered mental status remainedNosocomial bacteremia
Escherichia  coli
Mortality
Antibiotic  therapy
independently associated with mortality. Mental confusion can be a risk factor for mortality
in  patients with E. coli bacteremia.
heart  failure, neoplasm, chronic obstructive pulmonary dis-
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDThe main risk factors for bacteremia caused by Escherichia coli
include admission at the intensive care unit, previous antibi-
otic  use, invasive disposal (mainly urinary catheter) and
comorbidities. The mortality of bacteremia caused by E. coli
acquired  in the hospital is greater than when acquired in
the  community acquired.1 Furthermore, mortality can be
associated  with source of bacteremia, which is lower when
originated from the urinary tract.2 The objective of this report
was  to determine the predictive risk factors for mortality in
E.  coli bacteremia.
From January 2009 to January 2011 a retrospective cohort
study  was  carried out at the Hospital Universitario Evan-
gelico  de Curitiba, a reference center for trauma, burn and
renal  transplant. This center is a 660-bed tertiary-care hos-
pital  in Curitiba, a city located in Southern Brazil with 60
intensive  care beds. This study was  approved by the Ethics
Review  Board (CONEP PR – 448689). Patients with nosocomial
∗ Corresponding author at: Division of Infectious and Parasitic Diseases, H
1908 (4o. Andar), Bigorrilho, Curitiba, PR 80730-150, Brazil.
E-mail  address: ﬂptuon@gmail.com (F.F. Tuon).
1413-8670©  2013 Elsevier Editora Ltda. 
http://dx.doi.org/10.1016/j.bjid.2013.05.005
Este é um artigo Open Access sob a licençabacteremia caused by E. coli were evaluated. Exclusion criteria
were  age < 18 years, previous bacteremia, bacteremia occur-
ring  before 72 h of admission. Cultures were  collected and
processed  using the BACT/Alert® (bioMérieux, Durham, USA).
E.  coli was  identiﬁed using standard biochemical tests. Suscep-
tibility  testing was  performed by the disk diffusion method
according to the current CLSI guidelines.3
The following variables were evaluated for each patient:
sex,  age, previous hospital admission within 90 days, admis-
sion  to the intensive care unit, length of hospitalization
before bacteremia, central venous line, surgery during the
current  hospitalization, underlying conditions such as dia-
betes  mellitus, chronic renal failure (with or without dialysis),ospital Universitário Evangélico de Curitiba, Al. Augusto Stellfeld,
ease,  HIV infection, cirrhosis, trauma and burn. Previous or
concomitant  infection by E. coli was  evaluated. The suscepti-
bility  to quinolones and the presence of extended-spectrum
 de CC BY-NC-ND
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Table 1 – Clinical ﬁndings of nominal variables of 88
cases  of Escherichia coli bacteremia – 2012.
Data n = 88 %
Gender
Male 42 47.7
Female 46 52.3
Previous admission within 90 days 12 12.5
Final mortality 33 37.5
ESBL-producing strains 7 8.0
Quinolone-resistant strains 20 22.7
Previous admission to ICU 3 3.4
Central venous catheter 10 11.4
Surgery 8 9.1
Diabetes mellitus 23 26.1
Chronic renal failure 21 23.9
Heart failure 7 8.0
Essential systemic hypertension 32 36.4
Cancer (solid/leukemia/lymphoma) 21 23.9
Charlson score
0  40 45.5
1 3 3.4
2 35 39.8
3 4 4.5
4 6 6.8
Trauma 4 4.5
HIV 0 0.0
Chronic obstructive pulmonary disease 2 2.3
Cirrhosis 0 0.0
Previous infection 8 9.1
E. coli in other sites 11 12.5
Abscess 1 1.1
Peritoneal ﬂuid 1 1.1
Catheter tip 7 8.0
Urine 2 2.3
Previous use of antibiotics (>2 doses; >5
days before)
26  30.7
Days before
<10  days 10 11.3
10–15 days 6 6.8
>15 days 10 11.3
Cephalosporin (2nd, 3rd and 4th) 8 9.1
Carbapenem 3 3.4
Anaerobic antibiotics 10 11.4b r a z j i n f e c t d i
eta-lactamases were  included in the analysis. We  also
ncluded  Charlson comorbidity index score, previous use of
ntibiotics  in the same admission, mental status through
lasgow Coma Scale (GCS) in the day of the bacteremia as
linical  data. The following laboratory results were evaluated
n  the day of bacteremia: hemoglobin level, leukocyte and
latelet  counts, percentage of immature cells, creatinine, and
otal  bilirubin. Thirty-day in hospital mortality was  registered.
ttributed mortality was  not evaluated. Antibiotic treatment
as  classiﬁed as correct or incorrect, considering as correct if
. coli was  susceptible to the antibiotic used during bacteremia.
e  evaluated separately the time from positive blood culture
o  start of the correct antibiotic (<24 h, <48 h, <72 and <5 days).
Continuous  data were  expressed as mean ± standard devi-
tion  (SD) or median with ranges (when a considerable
iscrepancy was  observed between mean media). Frequencies
ere  expressed as percentages. Dichotomous variables were
ompared  using Chi-square and Mann Whitney test was used
or  continuous variables. Signiﬁcance level was  set at 0.05.
ariables  with p < 0.10 in univariate analysis were included
n  the multivariate analysis using binary logistic regression
odel.  Odd ratios (OR) with 95% conﬁdence intervals (95%
I)  were  calculated for each variable. Variables in which 95%
I  did not include 1.0 were maintained in the ﬁnal model.
aplan–Meier survival estimates were  calculated for risk fac-
ors  found in the multivariate analysis and the difference was
ssessed  using the log-rank test. Logistic regression was used
o  predict a score of mortality in patients with E. coli bac-
eremia  according to the risk factors. All data were stored
sing  the software Excel (Microsoft, New York, USA) and sta-
istical  analysis was performed using the software SPSS 16
SPSS,  Chicago, USA). Kaplan–Meier survival estimates were
etermined  with GraphPad Prism 5.0 (GraphPad, La Jolla, USA).
Eighty-eight  cases were enrolled in the study. The median
ays  of hospitalization before bacteremia was  16 (range = 3–36
ays)  with inter quarter percentiles (25% and 75%) between
.2  and 20 days, respectively. The mean age was  59.7 ± 17.3
range  = 18–96) years and 52.3% were female. Nominal data are
etailed in Table 1. Only seven cases (8.0%) of ESBL-producing
.  coli were  isolated. The total duration of hospitalization was
4.6  ± 24.0 days. Most patients had anemia (mean hemoglobin
0.3  ± 2.3 g/L), leukocytosis (14.3 ± 11.8 × 109/L) with increased
ercentage of immature cells (17.8 ± 14.7%), renal failure
mean  serum creatinine of 3.7 ± 7.2 and media of 1.5, range
.8–4.8)  and hiperbilirrubinemia (mean total bilirrubin of
.9  ± 3.9 and media 1.4, range 0.8–2.8).
The  30-day mortality was  37.5% with a median survival
ime  of 10 days of hospitalization after bacteremia. Mortal-
ty  rate was  not different with the correct or incorrect therapy.
he  patients who  received correct therapy within 24 h did not
iffer  from those who received within 72 h, probably due to
ew  patients included in these subgroups. In univariate analy-
is,  chronic renal failure (p < 0.001), alteration of mental status
p  = 0.003), higher leukocytosis (17,215/mm3 and 12,668/mm3,
 = 0.007), and a higher index of Charlson (≥2, p = 0.027) were
ssociated  with increased mortality. In multivariate analy-
is  only alteration of mental status was  an independent risk
actor  of mortality. A Kaplan–Meier curve was  evaluated for
ental  status conﬁrming the tendency of higher mortality in
he group of patients with this neurological alteration (Fig. 1).Quinolones 8 9.1
Mental confusion or sedation 14 15.9
Some conclusions of this study have been described by
other  authors, such as chronic renal failure.4 Mental status,
comorbidities, and leukocytosis are included in the APACHE
data,  which was  not assessed in this study because most
patients  were  not in the intensive care unit. However, in the
multivariate  analysis, only alteration of mental status was an
independent risk. This ﬁnding suggests that the infection was
severe  in these patients, and the encephalopathy can be a
marker  of mortality among patients with E. coli bacteremia.
Inadequate antibiotic therapy was not associated with
increased mortality, probably due to the low mortality rate
associated  with E. coli in contrast to other gram negative
bacilli.5–7 In our analysis, a beta error can explain the lack
of  difference in mortality in those who received inadequate
therapy. The percentage of ESBL-producing E. coli was  low
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Fig. 1 – Kaplan–Meier survival curves in patients with
bacteremia caused by E. coli according to presence of
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9mental  confusion (p < 0.001).
(<10%) as previously described in a surveillance program in
Brazil.8,9
In conclusion, this retrospective study in one center did not
ﬁnd  any signiﬁcant relationship between mortality and antibi-
otic  therapy adequacy, and mental confusion was  a predictor
of  death in patients with E. coli bacteremia.Conﬂicts  of  interest
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